|  |  |  |  |
| --- | --- | --- | --- |
| **Genotype 1**  **HCV Medication Posology** Epclusa® (Sofosbuvir 400mg and Velpatasvir 100mg) 1tablet daily **Harvoni® (Sofosbuvir 400mg and Ledipasvir 90mg) 1 tablet daily**  **Maviret ® (Glecaprevir 100mg and Pibrentasvir 40mg) 3 tablets daily**  **Vosevi® (Sofosbuvir 400mg, Velpatasvir 100mg andvoxilaprevir 100mg)**  **Zepatier® (50 mg Elbasvir and 100 mg Grazoprevir) 1 tablet daily**  **Copegus® (Ribavirin 200mg Tablets)**  **<65Kg 400mg twice daily, 65-85Kg 400mg mane + 600mg Nocte, >85Kg 600mg Twice daily** | **No or minimal fibrosis**  **Fibroscan less than 7** | **Moderate to severe fibrosis**  **Fibroscan more than 7 and less than 11** | **Known cirrhosis**  **Fibroscan more than 11** |
| **G1a and 1b**  **Treatment naive** | **Maviret 8 weeks**  **Harvoni 8 weeks**  **Zepatier 12 weeks \*** | **Maviret 8 to 12 weeks**  **Harvoni 8 to 12 weeks**  (discuss at MDT)  **Zepatier 12 weeks\*** | **Maviret 12 weeks**  **Harvoni 12 weeks**+/-**weight based Ribavirin \***  **Zepatier 12 weeks**  (discuss at MDT if platelets <100, albumin <30 or other signs of decompensation present) |
| **G1 and 1B**  **Treatment experienced**  **(DAA naive)** | **Maviret 12 weeks**  **Harvoni 12 weeks**  **Zepatier 12 weeks\*** |
| **\*If viral load >800,000 test for NS5a RAVs and if present give 16 weeks Zepatier and Weight based ribavirin** | | | |
| **G1b** | **If using Zepatier 12 weeks, no RAV testing** | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Genotype 2** | **No or minimal fibrosis**  **Fibroscan less than 7** | **Moderate to severe fibrosis**  **Fibroscan more than 7 and less than 11** | **Known cirrhosis**  **Fibroscan more than 11** |
| **G2**  **All** | **Maviret 8 weeks**  **Epclusa 12 weeks** | **Maviret 8 to 12 weeks**  (discuss at MDT)  **Epclusa 12 weeks** | **Maviret 12 weeks**  **Epclusa 12 weeks** |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Genotype 3** | **No or minimal fibrosis**  **Fibroscan less than 7** | **Moderate to severe fibrosis**  **Fibroscan more than 7 and less than 11** | **Known cirrhosis**  **Fibroscan more than 11** | **Genotype**  **4 / 5 / 6** | **No or minimal fibrosis**  **Fibroscan less than 7** | **Moderate to severe fibrosis Fibroscan more than 7 and less than 11** | **Known cirrhosis**  **Fibroscan more than 11** |
| **G3**  **Treatment naïve** | **Maviret 8 weeks**  **Epclusa 8 weeks** | **Maviret 8 to 12 weeks**  **Epclusa 8 -12 weeks**  (discuss at MDT) | **Maviret 12 weeks**  **Epclusa**+/- **weight based ribavirin 12 weeks**  (discuss at MDT if platelets <100, albumin <30 or other signs of decompensation present) | **G4**  **All** | **Maviret 8 weeks**  **Harvoni 8 weeks**  **Zepatier 12 weeks \*** | **Maviret 8 to 12 weeks**  **Harvoni 8 to 12 weeks**  (discuss at MDT)  **Zepatier 12 weeks\*** | **Maviret 12 weeks**  **Harvoni 12 weeks**+/-**weight based Ribavirin \***  **Zepatier 12 weeks**  (discuss at MDT if platelets <100, albumin <30 or other signs of decompensation present) |
| **G3**  **Treatment failures** | **Maviret 16 weeks**  **Epclusa 12 weeks** |
| **DDA Treatment Failure** | **Patients who relapse and don’t achieve an SVR on the above DDA regimens should be reviewed by the MDT for consideration of which regimen would be most suitable. Consider genotypic resistance testing. Choice will depend on measured or predicted resistance based on previous regimen used.** | | | **G5 / G6** | **No evidence available, discuss at MDT** | | |
| **All genotypes** | **Vosevi 12 weeks** | | |  |  | | |